Seegene and Werfen finalize partnership agreement on technology sharing initiative
Tuesday, October 15, 2024
Seegene Inc., a leading South Korean company providing a total solution for PCR molecular diagnostics, today announced the completion of a partnership agreement with Werfen, a global leader in specialty diagnostics, on the technology sharing initiative. Under the agreement, Seegene and Werfen will establish a NewCo in Spain, Werfen-Seegene, upon obtaining the required government approvals, expected in the first half of 2025.
This partnership is part of the dynamic technology sharing initiative, which includes the first NewCo partnership in March 2023 with Hylabs, a leading diagnostics company in Israel.
The technology sharing initiative aims to share Seegene’s advanced diagnostic and data analysis technologies globally, including real-time syndromic PCR tests and an automated product development system (SGDDS), with a leading partner company in each country. Seegene’s real-time syndromic PCR technology represents a breakthrough in molecular target detection. It can simultaneously detect up to 14 pathogens in a single reaction tube, with quantitative information for each target.
The partner companies will collaborate with local scientists and experts to develop diagnostic tests tailored to the needs of their communities and fields, covering a wide range of human and non-human diseases. In the face of the challenges of climate change and the expected increase in epidemics, the ultimate vision of the initiative is to create “a world free of all diseases”, a future where people no longer suffer from infectious diseases and cancers and animals and plants thrive without disease.
Werfen-Seegene will prioritize the development of products for infectious diseases, including antimicrobial and drug resistance tests, viral load tests, surveillance tests for organ transplant patients, sexually transmitted infections (STIs) and emerging diseases specific to the region. NewCo will leverage Werfen’s extensive local infrastructure and network to provide products tailored to local needs, contributing to healthcare in Spain.
As the fourth largest European in vitro diagnostic (IVD) market, Spain is poised to serve as a strategic hub for this expansion. Therefore, NewCo is expected to lead efforts to obtain In Vitro Diagnostic Medical Device Regulation (CE-IVDR) approval and expand into European and global markets.
“Over the past decade, our collaboration with Seegene has demonstrated the significant impact of its syndromic PCR testing on healthcare. We are excited to leverage Seegene’s unmatched technology and manufacturing expertise to develop products tailored to the Spanish and Portuguese markets, which are experiencing high demand for rapid product development due to the frequent emergence of new infectious diseases and viral mutations. Through this partnership with Seegene, we will be able to expand our presence and respond rapidly to any outbreak,” said Carlos Pascual , CEO of Werfen.
“We have high expectations for this NewCo, which will combine Werfen’s extensive commercial experience with Seegene’s advanced syndromic product development and manufacturing capabilities. We will continue to share our technology with leading international companies and countries interested in our technology sharing initiative. Werfen-Seegene will play a vital role in accelerating the global expansion of our initiative,” said Dr. Jong-Yoon Chun , CEO and Founder of Seegene.
Seegene has also entered into major strategic partnerships for this initiative with Microsoft and Springer Nature. The goal of the partnership with Microsoft is to enable global companies participating in the technology sharing initiative to have a streamlined product development system, enhanced by advanced IT system operations and AI-powered data analytics. Springer Nature is driving innovation in PCR diagnostic products through its Open Innovation Program (OIP), which was launched in 2023, followed by the Nature Awards MDx Impact Grants in 2024. It plans to expand and advance this program to help NewCos collaborate with local scientists and experts to develop innovative products in broad areas.
About Seegene
Seegene has 24 years of experience in research and development, manufacturing and business in real-time syndromic PCR technologies. This expertise was highlighted during the COVID-19 pandemic, when Seegene provided more than 340 million COVID-19 tests to over 100 countries worldwide. The key feature of Seegene’s real-time syndromic PCR technologies is the ability to simultaneously test 14 pathogens that cause similar symptoms in a single tube and provide quantitative results.
Visit Seegene.com and follow the profile linkedin.com/company/seegene-inc
About Werfen
Founded in 1966, Werfen is an international developer, manufacturer and distributor of specialty diagnostic instruments, related reagents, automated work cells and data management solutions, used primarily in hospitals and independent clinical laboratories. The company’s segments include hemostasis, acute care diagnostics, transfusion, autoimmunity and transplantation. Werfen operates directly in over 30 countries and through distributors in over 100 territories.
For more information, visit werfen.com
Source: prnewswire.com